Abstract: The present disclosure provides materials and methods related to the purification of a biologic from a biological fluid. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production of a biologic.

Abstract: The present disclosure provides methods related to the purification of a biologic. In particular, the present disclosure methods for purifying a biologic using a multifunctional chromatography medium comprising porous beads or particles having a defined pore diameter distribution and one or more ligands conjugated to the surface of the pores capable of removing process-related impurities and product-related impurities from a target biologic.

Abstract: The present disclosure provides materials and methods related to the purification of a biologic. The present disclosure provides materials and methods related to the purification of a biologic. In particular, the present disclosure provides a multifunctional chromatography medium comprising porous beads or particles having a defined pore diameter distribution and one or more ligands conjugated to the surface of the pores capable of removing process-related impurities and product-related impurities from a target biologic.

Abstract: The present disclosure provides compositions, methods, and systems related to a dual-affinity ratiometric quenching bioassay. In particular, the present disclosure provides novel compositions and methods that combine selective biorecognition and quenching of fluoescence signals for rapid and sensitive quantification of proteins in complex samples.

Abstract: Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.

Abstract: The present disclosure provides compositions and methods related to the purification and/or isolation of ?-1 antitrypsin (AAT). In particular, the present disclosure provides novel peptide ligands capable of binding recombinantly produced ?-1 antitrypsin to facilitate its isolation and/or purification from processing fluid streams for subsequent therapeutic use.

Abstract: The present invention provides synthetic peptides comprising an amino acid sequence of any one of SEQ ID NOs: 1-17 or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs:1-17. Also described herein are solid supports including peptides and methods of using such peptides and solid supports.

Abstract: The present disclosure provides compositions, methods, and systems related to a dual-affinity ratiometric quenching bioassay. In particular, the present disclosure provides novel compositions and methods that combine selective biorecognition and quenching of fluorescence signals for rapid and sensitive quantification of antibodies in complex samples.

Abstract: Aldehyde generation includes providing a first input stream, a second input, and an alkene substrate to a reactor system. The first input stream includes a catalyst, a ligand, and an organic solvent. The second input stream includes a mixture of carbon monoxide (CO) and hydrogen gas (H2). The alkene substrate is in either gaseous form or liquid form, the liquid form of the alkene substrate being provided with the first input stream, the gaseous form of the alkene substrate being provided with the second input stream. The reactor system includes a first reactor and a second reactor, where the second reactor is gas permeable and positioned within the first reactor.

Abstract: Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.

Abstract: Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.

Abstract: Described are compositions and methods for removing one or more host cell proteins from a mixture. The composition comprises one or more peptides wherein each peptide in the composition has a greater binding affinity for the one or more host cell proteins than for one or more target biomolecules.

Abstract: Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.

Abstract: Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.

Abstract: Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.

Abstract: Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.

Abstract: Pharmaceutical compositions comprising two or more therapeutically active agents, such as two or more anticancer agents, conjugated to one or more biocompatible polymers, wherein the molar ratio of the agents and/or schedules of delivery provide a synergistic therapeutic effect, are described. Methods of making and using the pharmaceutical compositions are further described. In one embodiment, the pharmaceutical compositions contain topoisomerase I and topoisomerase II inhibitors conjugated to the same or different biocompatible polymers. The two or more anticancer agents are covalently coupled to the polymer(s), and thereby can be delivered to a tumor at a molar ratio which provides a synergistic effect. Optionally, the agents are coupled indirectly to the polymer(s) via a linker.

Abstract: Provided herein are novel hyaluronic acid-based materials for in-situ gelation in wounds and other contexts, which materials are biocompatible and which have favorable gelation kinetics. The resulting hydrogels have desirable rheological properties. The invention encompasses novel reagents for forming crosslinked hyaluronic acid hydrogels, with favorable kinetics for medical applications and having desirable and tunable physical properties. Also presented herein are methods of using the novel materials disclosed herein in wound care and other medical contexts.

Abstract: This invention relates generally to the discovery of novel protease-resistant peptide ligands and uses thereof. Specifically, the present invention provides a protease-resistant peptide with three to twenty amino acids capable of binding a biological and comprising one or more basic amino acid(s) and I or aromatic amino acids, wherein one or more of the amino acids is substituted with a non-naturally occurring amino acid analog.

Abstract: Skin penetrating polypeptide and pharmaceutical compositions and methods of use thereof are provided. Typically, the peptides are between 3 and 100 amino acids, more preferably about 5, 6, 7, 8, 9, or 10 amino acids, cyclic, binds to a skin protein such as a keratin with a Kd of between about 10-3 M and about 10-8 M. Preferably the peptides increase absorption or penetration of an active agent into the skin. In silico methods of screening for skin protein binding polypeptides are also provided.